Immunic Inc. (IMUX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, IMUX scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together signal that the business is not currently generating cash returns and that insider activity offers little confirmation. The forensic balance sheet and macro pillars sit at mid-low levels, meaning the company is neither clearly distressed nor clearly stable. Upside drivers would need to come from clinical or regulatory developments rather than current cash generation, and any valuation case rests on those outcomes rather than on present fundamentals. Because the rating is driven by negative ROIC and zero FCF yield, the stock's price reflects expectations that the source data does not quantify. This is an analytical framing of the rating, not personalized financial advice.

Immunic Inc. (IMUX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.1B. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the listed fiscal years.

Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash declined from $35.7M in FY 2024 to $15.5M in FY 2025 while operating losses persisted across all three listed periods.

• Market wire items (Yahoo! Finance Canada, Seeking Alpha, Stock Titan, and a siam.in-sourced item) were flagged YELLOW and cover IMUX market action and fundamental catalysts without specific detail in the source data.
• A Simply Wall St item was flagged GREEN as a CATALYST and carries the headline: "We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully."
• A Stock Titan item reports a statistic that patients on an experimental multiple sclerosis drug were 2.47 times as likely to show disability improvement; the source does not provide trial design or context.
• A Stock Titan item references an online expert discussion on progressive multiple sclerosis.
• A siam.in-sourced item reports the stock rose 4.35% to $6.95, pressing toward the upper end of a recent range, tagged as a pairs trade.
• Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Risk watch items: negative operating income, declining reported cash, and the absence of revenue.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data beyond the sector and industry classification. A prospective investor should note that the source contains no mapped dependencies, so any ripple analysis would require information outside this dossier.

• What is the status and timeline of the experimental multiple sclerosis program referenced in the news wire, and what is its regulatory pathway?
• How does reported cash of $15.5M compare to annual free cash outflow of $-86.0M, and what financing sources are available?
• What products or revenue streams, if any, are expected, given reported revenue of $0.0M?
• What is the share count and dilution history, since EPS is reported as N/A?
• What institutional or insider holdings exist, given that the holders section is unavailable?